Skip to content

Buying a Pharmacy

Share Purchase vs Asset Purchase for a Pharmacy: the Tax and Structuring Trade-Off

11 November 2026 · 9 min read

Get in touch

The short answer: two taxes, two trade-offs

A share purchase and an asset purchase are taxed differently at entry, and they carry different risks and administrative steps afterwards. In brief: a share deal attracts 0.5% stamp duty on the share consideration but you acquire the company and everything it has ever done. An asset deal attracts SDLT on any property at non-residential and mixed-use rates up to 5% but you take a cleaner slate on the trade. For a pharmacy, two further twists matter: the NHS contract and GPhC registration mechanics differ by structure, and goodwill (which dominates pharmacy pricing) attracts restricted corporation tax relief on a company purchase.

Neither structure is universally better. The right answer depends on the deal, the seller's history, and your tax position.

What a share purchase is

You buy the shares in the company that owns and operates the pharmacy. The company itself does not change: it continues to hold its assets, its liabilities, its contracts, its HMRC registrations, and its trading history. You become the new shareholder; the company carries on as before, subject to any notifications or consents required by third parties.

The practical consequence is that you inherit everything the company has ever done. Outstanding VAT assessments, PAYE underpayments, supplier disputes, lease obligations, and any contingent legal claims all come with the deal. This is why a share purchase involves detailed due diligence and why warranties and indemnities from the seller are not optional extras: they are the contractual mechanism for allocating risks the buyer cannot fully verify before completion.

The entry tax is low. You pay stamp duty at 0.5% on the consideration paid for the shares. On a £1,000,000 share deal that is £5,000. There is no SDLT on a share purchase, regardless of whether the company owns freehold premises. Stamp duty on shares is due to be replaced by the Securities Transfer Tax, announced for late 2027 by commencement order.

What an asset purchase is

You buy specified assets from the company or sole trader: the stock, equipment, goodwill, and (if applicable) the freehold or leasehold premises. The seller retains the corporate entity and its history. You start with a new legal vehicle and take only what you have agreed to acquire.

The trade-off is the entry tax on property. If the deal includes freehold premises, or a leasehold with a premium, SDLT applies at non-residential and mixed-use rates. Those rates run to 5% above £250,000 of consideration. On a pharmacy premises purchase of £500,000, the SDLT bill could be materially higher than the stamp duty on a share deal covering the same underlying value.

Where the pharmacy is leasehold and you take over the existing lease, you only pay SDLT on any price you pay for the lease, so with no premium there's none. A new lease granted to you is different: it pays SDLT on the net present value of the rent, at 1% from £150,001 to £5 million and 2% above. Where no property changes hands at all, there's no SDLT, and the asset deal's entry tax can be very competitive.

The tax on entry: a worked illustration

The table below uses an illustrative pharmacy acquisition at £1,200,000 total consideration, with £400,000 attributed to freehold premises in the asset deal scenario. All figures are illustrative only; your transaction will have different values and a different property allocation.

Share purchase Asset purchase
Total consideration £1,200,000 £1,200,000
Tax base for entry duty Share consideration: £1,200,000 Property element only: £400,000
Rate / calculation Stamp duty at 0.5% SDLT: non-residential rates (0% on first £150,000, 2% on £150,001 to £250,000, 5% above £250,000)
Entry tax (illustrative) £6,000 £9,500 (0 + £2,000 + £7,500)
Entry tax differential Share deal cheaper at entry by ~£3,500 in this example

This illustration is for structure comparison only. The entry tax gap narrows or reverses depending on the property value, lease terms, and total consideration. Where premises are leasehold with no capital premium, the asset deal's SDLT exposure can fall substantially. Where the freehold value is high, the SDLT on an asset deal rises steeply. Run the actual numbers for your deal.

Add the purchase price, deposit, loan terms and projected profit to see the monthly repayment, the post-tax cash cover and the stamp duty or SDLT on a share deal against an asset deal.

Calculator

Pharmacy Purchase Affordability Calculator

Enter the purchase price, deposit, loan terms and projected pharmacy profit to see your estimated loan repayments, how well trading cash flow covers the debt, and the acquisition tax cost for a share deal versus an asset deal. Every figure already in the boxes is an example, so replace it with your own; the result on your deal depends on how it's structured.

£

The agreed headline price for the pharmacy. Enter the actual figure from your heads of terms.

£

The amount you are putting in from your own funds. The rest is assumed to be financed by a commercial loan.

The term your lender offers. Shorter terms mean higher repayments but less total interest.

The rate quoted by the lender. The rate you are offered depends on lender, term and loan-to-value.

£

The part of the price that buys land or buildings: a freehold, or what you pay for a lease. Leave at 0 if no property is being bought. SDLT is charged on this figure only, never on goodwill or the NHS contract.

£

Only if you're taking a new lease of the premises. SDLT is due on the rent's net present value at 1% from £150,001 to £5 million and 2% above. HMRC's SDLT calculator works the figure out from the rent and the term.

£

The adjusted EBITDA or trading profit you expect after your salary, before loan interest and tax. The tool takes the first year's interest off before working out corporation tax.

Your result

Your answer's ready. Press below to see it.

The pharmacy twist 1: NHS contract and GPhC continuity

For a general business, the share-vs-asset structuring decision is mostly a tax and liability question. For a pharmacy it also engages the NHS contract and the GPhC registration, which operate differently depending on how the deal is structured.

Market entry in England is governed by the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The NHS contract is the asset: it is what generates the reimbursement and remuneration income. Continuity of that contract through completion is essential.

On a share deal, the company continues to hold the NHS contract. You are buying the company, not assigning the contract. The company's contractor status does not change at the point of share transfer, but the company has to tell NHS England within 30 days of new directors or a new superintendent (Schedule 4 paragraph 32 of the 2013 Regulations). It's a completion mechanic to plan in advance, not an afterthought.

On an asset deal, the NHS contract does not automatically transfer with the assets. You apply to NHS England to be included in the pharmaceutical list in the seller's place (a change of ownership application, regulation 26 of the 2013 Regulations); a listing can't be assigned. This can take time and carries some market-entry risk that does not exist in a share deal. Legal advice specific to the contract type and NHS region is essential before structuring a pharmacy acquisition as an asset deal.

The premises have to be entered in the GPhC register, and a new entry depends on the applicant lawfully running a retail pharmacy business there (Medicines Act 1968 ss74A, 74B); a company running one also needs a superintendent pharmacist (s71). On a share deal the company running the pharmacy doesn't change. On an asset deal you're the new person running it, so the premises entry and, if you buy through a company, the superintendent need settling before you trade. Your solicitor handles the registration steps.

Neither structure makes NHS contract or GPhC continuity impossible, but the path and the risks differ. The share deal is generally lower-risk on contract continuity; the asset deal requires more regulatory groundwork.

Want this checked against your specific situation?

Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.

We'll only use your details to respond to your enquiry. We don't pass them to any other firm. See our Privacy Policy.

The pharmacy twist 2: goodwill and the CT-relief restriction

Pharmacy pricing is dominated by goodwill. The NHS contract, item volume, and location drive a pharmacy's value far more than its tangible assets. This makes the tax treatment of goodwill in the buyer's hands a material planning question.

On a share purchase, the goodwill sits on the balance sheet of the company you are buying. You buy shares, not goodwill, and the goodwill stays a company asset, so check the target's own goodwill tax position in due diligence.

On an asset purchase, you (or your new vehicle) acquire the goodwill directly. Under current HMRC rules, corporation tax relief on goodwill is restricted and only available in limited cases at fixed rates: a company buying the business on or after 1 April 2019 gets a fixed 6.5% a year only if qualifying IP assets come with it, on no more than six times what that IP cost. The generous amortisation deductions that were once available on acquired goodwill are no longer the default. Given that goodwill can be a very large number in a pharmacy transaction, the restricted CT relief is a real after-tax cost that must be modelled when comparing the two structures.

The practical effect is that an asset deal can look cheaper on entry tax (particularly where there are no premises) but your company's relief on the goodwill it buys is limited to the IP rule above, so don't expect to deduct the goodwill cost at an ordinary amortisation pace. The interaction between SDLT savings, goodwill CT relief, and the buyer's corporation tax rate needs to be worked through for the specific deal before structure is finalised.

The full side-by-side comparison

Dimension Share purchase Asset purchase
Entry tax on consideration 0.5% stamp duty on shares SDLT on property at non-residential rates up to 5%; no stamp duty on non-property assets
History and liabilities inherited All company history: tax liabilities, VAT, PAYE, legal claims, supplier disputes. Warranties and indemnities are the backstop. Only what is specified in the asset purchase agreement. Prior liabilities stay with the seller's entity.
NHS contract continuity Company retains the contract; it has to tell NHS England within 30 days of new directors or a new superintendent. Lower completion risk. Contract does not pass with assets automatically. Buyer applies to NHS England to take the seller's place in the pharmaceutical list under the 2013 Regulations. Higher completion risk; requires advance planning.
GPhC registration steps Registered premises continue under the same company. Superintendent arrangements continue subject to any personnel changes. The premises entry depends on you lawfully running the business there (Medicines Act 1968 ss74A, 74B), and a buying company needs a superintendent (s71); your solicitor handles the steps (see the GPhC's pharmacy pages).
Goodwill CT relief (buyer) Goodwill stays on the company's balance sheet. CT relief question is within the company's own accounts. Buyer acquires goodwill directly. CT relief is restricted and only available in limited cases at fixed rates: a company buying the business on or after 1 April 2019 gets a fixed 6.5% a year only if qualifying IP assets come with it, on no more than six times what that IP cost. Material cost given goodwill dominance in pharmacy pricing.
Due diligence depth Must cover the whole company history: tax, employment, legal, regulatory. Higher due-diligence burden reflects the inherited risk. Focused on the assets acquired and the change of ownership application. Narrower scope but the NHS contract path requires specialist legal input.
Warranties and indemnities Central to the deal. Seller warrants the company's history; indemnities cover specific identified risks. Less extensive on historical liabilities, but the change of ownership application to NHS England and the GPhC premises entry need contractual protection.

Which structure is usually right?

There is no universal answer. Both structures are used for pharmacy acquisitions, and the right one depends on the specific deal. These are the questions that drive the decision:

  • What is the property situation? A high-value freehold makes the SDLT on an asset deal significant. A short leasehold with no premium removes much of the entry-tax argument for a share deal.
  • How clean is the seller's company history? A company with a complex PAYE history, pending VAT queries, or prior litigation creates inherited risk that may tip the buyer toward an asset deal despite the higher entry tax.
  • How material is the goodwill CT-relief restriction? Where goodwill is a very large number (goodwill dominates a pharmacy's price), the restricted CT relief on an asset purchase is a real after-tax cost to model alongside any SDLT saving at entry.
  • How urgent is completion, and what is the NHS contract risk? A share deal offers a more straightforward path on contract continuity. If timeline pressure is real, the asset deal's change of ownership application to NHS England needs to be planned before heads of terms are signed.

The worked illustration above shows a single scenario. Your deal will have different numbers, different property, and a different seller history. The correct structure is the one that produces the best after-tax outcome for your specific facts, after accounting for due diligence risk, goodwill CT relief, and NHS contract continuity.

For a full breakdown of the buying process from heads of terms to completion, see the pharmacy buyer's checklist. For the valuation mechanics that drive the goodwill number at the heart of both structures, see the pharmacy goodwill guide. If you are financing the acquisition, the first-time buyer finance guide covers how structure interacts with what lenders will fund.

The pharmacy purchase affordability calculator can help you stress-test the numbers at different consideration levels. It also sets the share deal's stamp duty against the asset deal's SDLT on the premises and any new lease; use it as a scenario tool rather than a tax computation.

If you are at the structuring stage of a pharmacy acquisition, the decisions made now affect the entry tax, the after-tax cost of goodwill, and the NHS contract path through completion. Find out how we support pharmacy buyers or explore the pharmacy purchase accounting service for the full scope of work involved.

Frequently asked questions

Both are used, and neither is the default. A sole trader or partnership can only sell the business's assets; a company seller can sell either its shares or its business. The right structure depends on the deal facts, the seller's company history, and the buyer's tax position.

You pay stamp duty at 0.5% on the consideration paid for the shares, on a transaction over £1,000, rounded up to the nearest £5. The announced Securities Transfer Tax is due to replace stamp duty on shares in late 2027, by commencement order. See gov.uk/tax-buy-shares for the current rate and exemptions.

Yes, on any property in the deal (England and Northern Ireland; Wales and Scotland have their own taxes). A freehold pays SDLT at non-residential rates, which rise to 5% above £250,000. If you take over the existing lease, you only pay SDLT on any price you pay for it; a new lease pays SDLT on the net present value of its rent, at 1% from £150,001 to £5 million and 2% above. The 0.5% stamp duty on shares does not apply in an asset deal.

Everything the company holds: its assets, its NHS contract (subject to notification), its VAT history, its PAYE history, any outstanding HMRC liabilities, any supplier disputes, and any contingent legal claims. Warranties and indemnities from the seller are the contractual backstop.

On a share purchase, the goodwill stays on the balance sheet of the company you buy; you buy its shares, not the goodwill. On an asset purchase by your company, CT relief on the goodwill is restricted: a fixed 6.5% a year, and only where qualifying IP assets come with the business, on no more than six times what that IP cost (CTA 2009 s879B, s879I). This is a material planning point given how much of a pharmacy's price is goodwill.

On a share deal the company stays on the pharmaceutical list; you are buying the company, not assigning the contract. The company has to tell NHS England within 30 days of new directors or a new superintendent. The 2013 Regulations govern pharmacy market entry and contract continuity in England.

Related reading

Need help with your pharmacy finances?

Tell us about your situation and we will come back within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)